gamma-aminobutyric acid has been researched along with Colitis, Mucous in 21 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess effects of pregabalin on colonic compliance, sensory and motor functions in patients with constipation-predominant irritable bowel syndrome." | 9.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "In a pilot, double-blind, placebo-controlled, parallel-group study, we tested oral pregabalin, 200mg, in 18 patients with constipation-predominant irritable bowel syndrome." | 9.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "Pregabalin, 200mg, might not reduce distension-related colonic pain in constipation-predominant irritable bowel syndrome patients." | 9.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "In prior studies, pregabalin reduced rectal or colonic pain in patients with irritable bowel syndrome and healthy adults, suggesting reduction of afferent function." | 9.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "To evaluate the effects of gabapentin on sensory and motor function of the rectum in patients with diarrhoea-predominant irritable bowel syndrome." | 9.11 | Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. ( Cho, SW; Kim, JH; Lee, KJ, 2005) |
| "Our results show that gabapentin reduces rectal sensory thresholds through attenuating rectal sensitivity to distension and enhancing rectal compliance in diarrhoea-predominant irritable bowel syndrome patients." | 9.11 | Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. ( Cho, SW; Kim, JH; Lee, KJ, 2005) |
| "Gabapentin has been shown to reduce elements of central sensitization in human experimental hyperalgesia." | 6.71 | Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. ( Cho, SW; Kim, JH; Lee, KJ, 2005) |
| "To assess effects of pregabalin on colonic compliance, sensory and motor functions in patients with constipation-predominant irritable bowel syndrome." | 5.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "In a pilot, double-blind, placebo-controlled, parallel-group study, we tested oral pregabalin, 200mg, in 18 patients with constipation-predominant irritable bowel syndrome." | 5.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "Pregabalin, 200mg, might not reduce distension-related colonic pain in constipation-predominant irritable bowel syndrome patients." | 5.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "In prior studies, pregabalin reduced rectal or colonic pain in patients with irritable bowel syndrome and healthy adults, suggesting reduction of afferent function." | 5.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "To evaluate the effects of gabapentin on sensory and motor function of the rectum in patients with diarrhoea-predominant irritable bowel syndrome." | 5.11 | Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. ( Cho, SW; Kim, JH; Lee, KJ, 2005) |
| "Our results show that gabapentin reduces rectal sensory thresholds through attenuating rectal sensitivity to distension and enhancing rectal compliance in diarrhoea-predominant irritable bowel syndrome patients." | 5.11 | Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. ( Cho, SW; Kim, JH; Lee, KJ, 2005) |
| "Pregabalin, a ligand of alpha(2)delta subunits of voltage-gated calcium channels, reduces visceral hypersensitivity associated with irritable bowel syndrome." | 3.76 | Pregabalin inhibits accelerated defecation and decreased colonic nociceptive threshold in sensitized rats. ( Gale, JD; Kurebayashi, Y; Ohashi-Doi, K, 2010) |
| "Pregabalin, which binds to the alpha2-delta subunit of voltage-gated calcium channels, increased the threshold for pain during colorectal distension (CRD) in irritable bowel syndrome (IBS) patients." | 3.74 | Effects of pregabalin on visceral pain responses and colonic compliance in rats. ( Brusberg, M; Larsson, H; Lindström, E; Martínez, V; Ravnefjord, A, 2008) |
| "Gabapentin has been shown to reduce elements of central sensitization in human experimental hyperalgesia." | 2.71 | Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. ( Cho, SW; Kim, JH; Lee, KJ, 2005) |
| "Irritable bowel syndrome is regarded as the prototypic disorder of the brain-gut-microbiota axis that can be responsive to probiotic therapy." | 2.55 | The Microbiome-Gut-Brain Axis in Health and Disease. ( Cryan, JF; Dinan, TG, 2017) |
| "Currently, treatment of stress-related gastrointestinal disorders, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), is mainly symptomatic since there is no drug on the market that solves effectively diverse disease symptoms and comorbid states." | 2.55 | GABAergic System in Action: Connection to Gastrointestinal Stress-related Disorders. ( Auteri, M; Jembrek, MJ; Serio, R; Vlainic, J, 2017) |
| "The fecal microbiota during IBS symptom exacerbation exhibited significant differences in the phylogenic pattern and short-chain fatty acid compared with fecal samples during defecation when symptoms were not exacerbated." | 1.72 | Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation. ( Fukuda, S; Fukudo, S; Gotoh, Y; Hayashi, T; Kasahara, Y; Kawashima, J; Kurokawa, K; Mori, H; Nakamura, K; Sato, Y; Tanaka, Y; Yamashita, R, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Laroute, V | 2 |
| Beaufrand, C | 2 |
| Gomes, P | 2 |
| Nouaille, S | 1 |
| Tondereau, V | 1 |
| Daveran-Mingot, ML | 2 |
| Theodorou, V | 2 |
| Eutamene, H | 2 |
| Mercier-Bonin, M | 2 |
| Cocaign-Bousquet, M | 2 |
| Tanaka, Y | 1 |
| Yamashita, R | 1 |
| Kawashima, J | 1 |
| Mori, H | 1 |
| Kurokawa, K | 1 |
| Fukuda, S | 1 |
| Gotoh, Y | 1 |
| Nakamura, K | 1 |
| Hayashi, T | 1 |
| Kasahara, Y | 1 |
| Sato, Y | 1 |
| Fukudo, S | 1 |
| Zhang, M | 1 |
| Zheng, Y | 1 |
| Li, X | 1 |
| Wu, H | 1 |
| Liu, P | 1 |
| Zhang, K | 1 |
| Shi, Z | 1 |
| Lv, M | 1 |
| Wang, F | 1 |
| Tang, X | 1 |
| Aubry, N | 1 |
| Liebgott, C | 1 |
| Ballet, N | 1 |
| Legrain-Raspaud, S | 1 |
| Icenhour, A | 2 |
| Tapper, S | 2 |
| Bednarska, O | 2 |
| Witt, ST | 2 |
| Tisell, A | 2 |
| Lundberg, P | 2 |
| Elsenbruch, S | 2 |
| Walter, S | 2 |
| Cooper, TE | 1 |
| Heathcote, LC | 1 |
| Clinch, J | 1 |
| Gold, JI | 1 |
| Howard, R | 1 |
| Lord, SM | 1 |
| Schechter, N | 1 |
| Wood, C | 1 |
| Wiffen, PJ | 1 |
| Engström, M | 1 |
| Iturrino, J | 1 |
| Camilleri, M | 2 |
| Busciglio, I | 1 |
| Burton, D | 1 |
| Zinsmeister, AR | 1 |
| Zhang, MM | 1 |
| Liu, SB | 1 |
| Chen, T | 1 |
| Koga, K | 1 |
| Zhang, T | 1 |
| Li, YQ | 1 |
| Zhuo, M | 1 |
| Dinan, TG | 1 |
| Cryan, JF | 1 |
| Jembrek, MJ | 1 |
| Auteri, M | 1 |
| Serio, R | 1 |
| Vlainic, J | 1 |
| Ravnefjord, A | 1 |
| Brusberg, M | 1 |
| Larsson, H | 1 |
| Lindström, E | 1 |
| Martínez, V | 1 |
| Levy, BS | 1 |
| Ducrotté, P | 1 |
| Ohashi-Doi, K | 1 |
| Gale, JD | 2 |
| Kurebayashi, Y | 1 |
| Ghaith, O | 1 |
| El-Halabi, M | 1 |
| Hashash, JG | 1 |
| Sharara, AI | 1 |
| Lee, KJ | 1 |
| Kim, JH | 1 |
| Cho, SW | 1 |
| Houghton, LA | 1 |
| Fell, C | 1 |
| Whorwell, PJ | 1 |
| Jones, I | 1 |
| Sudworth, DP | 1 |
| Million, M | 1 |
| Wang, L | 1 |
| Adelson, DW | 1 |
| Roman, F | 1 |
| Diop, L | 1 |
| Taché, Y | 1 |
| Saad, RJ | 1 |
| Chey, WD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Evaluation of the Antidepressant Effect of the Use of Probiotics in Bipolar Disorder and Possible Mediating Effects of Systemic and Intestinal Inflammatory Markers in the Microbiota[NCT05762887] | 84 participants (Anticipated) | Interventional | 2023-01-09 | Recruiting | |||
| Gabapentin Treatment of Postural Tachycardia Syndrome (PoTS): a Pilot Study[NCT04345432] | 10 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for gamma-aminobutyric acid and Colitis, Mucous
| Article | Year |
|---|---|
Antidepressants for chronic non-cancer pain in children and adolescents.
Topics: Abdominal Pain; Adolescent; Amines; Amitriptyline; Analgesics; Antidepressive Agents; Child; Chronic | 2017 |
The Microbiome-Gut-Brain Axis in Health and Disease.
Topics: Animals; Autistic Disorder; Brain; Cytokines; Depression; Fatty Acids, Volatile; gamma-Aminobutyric | 2017 |
GABAergic System in Action: Connection to Gastrointestinal Stress-related Disorders.
Topics: Animals; Benzodiazepines; gamma-Aminobutyric Acid; Gastrointestinal Diseases; Humans; Inflammatory B | 2017 |
The complex nature of chronic pelvic pain.
Topics: Adult; Amines; Anti-Anxiety Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, | 2007 |
Investigational agents for the irritable bowel syndrome.
Topics: Amines; Cyclohexanecarboxylic Acids; Drugs, Investigational; Female; Gabapentin; gamma-Aminobutyric | 2010 |
Recent developments in the therapy of irritable bowel syndrome.
Topics: Animals; Antidepressive Agents; Calcium Channel Blockers; Corticotropin-Releasing Hormone; gamma-Ami | 2008 |
3 trials available for gamma-aminobutyric acid and Colitis, Mucous
| Article | Year |
|---|---|
Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome.
Topics: Adult; Analgesics; Colon; Compliance; Constipation; Double-Blind Method; Female; gamma-Aminobutyric | 2014 |
Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome.
Topics: Adult; Amines; Analgesics; Compliance; Cyclohexanecarboxylic Acids; Diarrhea; Double-Blind Method; G | 2005 |
Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome.
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Double-Blind Method; Female; gamma-Aminobutyric | 2007 |
12 other studies available for gamma-aminobutyric acid and Colitis, Mucous
| Article | Year |
|---|---|
Topics: Analgesics; Animals; gamma-Aminobutyric Acid; Humans; Irritable Bowel Syndrome; Lactococcus lactis; | 2022 |
Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation.
Topics: Butyrates; Diarrhea; Fatty Acids, Volatile; Feces; gamma-Aminobutyric Acid; Glutamine; Humans; Hydro | 2022 |
Tong-Xie-Yao-Fang alleviates diarrhea-predominant irritable bowel syndrome in rats via the GCN2/PERK-eIF2α-ATF4 signaling pathway.
Topics: Activating Transcription Factor 4; Animals; Body Weight; Caspase 3; Cysteine; Diarrhea; Drugs, Chine | 2022 |
Lactococcus lactis CNCM I-5388 versus NCDO2118 by its GABA hyperproduction ability, counteracts faster stress-induced intestinal hypersensitivity in rats.
Topics: Amino Acid Sequence; Animals; gamma-Aminobutyric Acid; Humans; Irritable Bowel Syndrome; Lactobacill | 2023 |
Elucidating the putative link between prefrontal neurotransmission, functional connectivity, and affective symptoms in irritable bowel syndrome.
Topics: Adult; Affective Symptoms; Case-Control Studies; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glu | 2019 |
Reduced excitatory neurotransmitter levels in anterior insulae are associated with abdominal pain in irritable bowel syndrome.
Topics: Abdominal Pain; Adolescent; Adult; Cerebral Cortex; Excitatory Amino Acid Agonists; Excitatory Amino | 2019 |
Effects of NB001 and gabapentin on irritable bowel syndrome-induced behavioral anxiety and spontaneous pain.
Topics: Adenosine Triphosphate; Amines; Animals; Anxiety; Behavior, Animal; Cyclohexanecarboxylic Acids; Gab | 2014 |
Effects of pregabalin on visceral pain responses and colonic compliance in rats.
Topics: Abdominal Pain; Administration, Oral; Analgesics; Animals; Blood Pressure; Calcium Channels; Colon; | 2008 |
[Irritable bowel syndrome: dietary and pharmacological therapeutic options].
Topics: Abdominal Pain; Analgesics; Anesthetics, Local; Anti-Bacterial Agents; Antidepressive Agents; Centra | 2009 |
Pregabalin inhibits accelerated defecation and decreased colonic nociceptive threshold in sensitized rats.
Topics: Abdominal Pain; Analgesics; Animals; Defecation; Dose-Response Relationship, Drug; gamma-Aminobutyri | 2010 |
alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Hyperalgesia; Irritable Bowel Syndrome; Ligands; Pain T | 2007 |
Pregabalin decreases visceral pain and prevents spinal neuronal activation in rats.
Topics: Analgesics; Animals; Colon; gamma-Aminobutyric Acid; Humans; Hyperalgesia; Irritable Bowel Syndrome; | 2007 |